Takeda Pharmaceutical Co. Ltd. and Seattle Genetics Inc. announced that data from the randomized phase III Alcanza clinical trial evaluating Adcetris (brentuximab vedotin) in patients with cutaneous T-cell lymphoma was published in Lancet.
Long-term data on patients treated with a standard chemoimmunotherapy combination show relapse rates dropped over time and 70% of patients were still alive 15 years later, with an overall cure rate estimated at 42% of patients treated, according to a study led by scientists at SWOG, Fred Hutch Cancer Center, and the University of Rochester Medical Center.
